Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L HartmanArun J SanyalRohit LoombaJonathan M WilsonAmir NikooienejadRoss BrayChrisanthi A KaranikasKevin L DuffinDeborah A RobinsAxel HauptPublished in: Diabetes care (2020)
In post hoc analyses, higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM.